As far as Internet villains go, it’s hard to find someone as hated as Martin Shkreli. Earlier this year, after acquiring the patent for a drug designed to treat Aids and cancer patients in chemotherapy, the greedy CEO of Turing Pharmaceuticals announced a 5,000% price hike – from $13.50 a pill to $750.
At the time, Shkreli tried to justify the price increase. He said that the drug, Daraprim, had originally been priced too low. The company needed to generate profits. Unsurprisingly, none of these excuses washed with the general public. And, lo and behold, the meme game was fierce:
Just when we thought the furore was beginning to die down, there’s now a twist. A competitor company Imprimis Pharmaceuticals has started selling its own version of the drug. And the best bit about it? They’re now offering the same drug for just $99 for 100 pills. Yep. That works out roughly $1 a pill.
This drug CEO just got owned. Massively.
While the new drug has yet to be approved by the FDA (the U.S. Food and Drug Administration), and it’s not exactly the same as Daraprim’s pill, the news has put Shkreli’s smarmy little face right in its place.
Imprimis CEO (and resident Good Guy) Mark L. Baum said in a press release: “Today, some drug prices are simply out of control and we believe we may be able to help control costs by offering compounded alternatives to special sole source legacy generic drugs.”
Oh how we laughed when we heard this news. Shkreli, you really have just been massively owned. Not that he really cares. When he was contacted by US Uncut for a comment on the case, Shkreli’s only response was, “lol.” We can’t wait to see what his next move is. Hopefully it’s down a big, dark well where he’ll stay for the rest of eternity.
Enjoyed the fact this drug CEO just got owned? Why not have a read of some of our other articles, including Black Sabbath Once Spent $75k In One Year On Cocaine and 7 Animals Who Make More Money Than You